Vitamin D Is Not a Vitamin — It Is a Steroid Hormone Precursor Whose Active Form (1,25-Dihydroxyvitamin D₃ / Calcitriol) Binds the VDR Nuclear Receptor to Regulate 3–5% of the Human Genome, and the 41% Prevalence of Deficiency in U.S. Adults (80% in Black Americans) Combined With the VITAL Trial's −25% Cancer Mortality Signal After Year 2 Makes Vitamin D Correction One of the Most Justified Supplementation Decisions Available
Updated: June 2026vitamin D · vitamin D supplement · vitamin D benefits · vitamin D deficiency · vitamin D and health · vitamin D importance · vitamin D why important · vitamin D steroid hormone · vitamin D calcitriol · vitamin D not a vitamin · vitamin D hormone · 25-hydroxyvitamin D · 25-OH-D · 25OHD · vitamin D blood test · vitamin D test · how to test vitamin D · vitamin D level · optimal vitamin D level · vitamin D sufficiency · vitamin D deficiency level · vitamin D insufficiency · vitamin D normal range · what is deficient vitamin D · VDR · vitamin D receptor · VDR nuclear receptor · calcitriol VDR · 1 25 dihydroxyvitamin D · active vitamin D · vitamin D gene expression · vitamin D genome · how many genes does vitamin D regulate · vitamin D transcription factor · vitamin D calcium · vitamin D calcium absorption · vitamin D intestinal calcium · TRPV6 vitamin D · calbindin vitamin D · calcium absorption gut · vitamin D and bone · vitamin D osteoporosis · vitamin D bone density · vitamin D fracture · vitamin D deficiency 41 percent · vitamin D deficiency prevalence · NHANES vitamin D · vitamin D Black Americans · vitamin D skin color · melanin vitamin D · vitamin D sunscreen · vitamin D sun · how much sun for vitamin D · UVB vitamin D · vitamin D synthesis skin · vitamin D latitude · vitamin D winter · vitamin D and race · vitamin D obesity · obesity and vitamin D · vitamin D cancer · vitamin D and cancer · vitamin D cancer mortality · VITAL trial · VITAL trial vitamin D · Manson 2019 · Manson VITAL · VITAL trial results · vitamin D 2000 IU VITAL · VITAL trial cancer · vitamin D cancer prevention · vitamin D cancer mortality reduction · vitamin D metastatic cancer · vitamin D cancer 25 percent · vitamin D cancer NEJM · omega-3 VITAL trial · VITAL trial omega-3 · vitamin D cardiovascular · vitamin D heart · vitamin D cardiovascular disease · vitamin D and heart disease · vitamin D immune · vitamin D immune function · vitamin D T cells · vitamin D and infection · vitamin D respiratory infection · vitamin D COVID · vitamin D influenza · vitamin D D3 vs D2 · vitamin D3 cholecalciferol · vitamin D2 ergocalciferol · D3 vs D2 · which vitamin D is better D2 or D3 · D3 more potent than D2 · vitamin D2 plant · vitamin D3 animal · calcifediol · calcifediol vitamin D · calcifediol vs D3 · 25-hydroxyvitamin D3 supplement · calcifediol bioavailability · vitamin K2 and D3 · vitamin K2 MK-7 · K2 and vitamin D · D3 K2 combination · why take K2 with vitamin D · K2 calcium routing · K2 MGP · matrix Gla protein · K2 arterial calcification · K2 osteocalcin · vitamin D dosage · vitamin D 1000 IU · vitamin D 2000 IU · vitamin D 5000 IU · how much vitamin D to take · vitamin D toxicity · vitamin D hypercalcemia · vitamin D upper limit · vitamin D with fat · best time to take vitamin D · vitamin D magnesium · magnesium and vitamin D · vitamin D cofactors
Vitamin D is chemically a secosteroid — a steroid with a broken B-ring — and its biologically active form (1,25-dihydroxyvitamin D₃, calcitriol) acts as a steroid hormone, not a vitamin. True vitamins cannot be synthesized by the body and must be obtained from diet; vitamin D is synthesized in human skin when 7-dehydrocholesterol is converted to previtamin D₃ by UVB photons (290–315 nm wavelength), then thermally isomerized to vitamin D₃ (cholecalciferol). Only populations with limited sun exposure — which in the modern industrialized world includes the majority of people at latitudes above 35°N in winter, all indoor workers, anyone using sunscreen (SPF 15 blocks 99% of UVB vitamin D synthesis), dark-skinned individuals at northern latitudes, and the elderly (reduced dermal 7-dehydrocholesterol) — require dietary or supplemental sources. This list describes most people in North America and Northern Europe for most of the year.
After skin synthesis or dietary absorption, cholecalciferol undergoes two hydroxylation steps: hepatic 25-hydroxylase (CYP2R1) → 25-hydroxyvitamin D₃ (calcidiol — the storage and serum form, measured clinically); then renal 1α-hydroxylase (CYP27B1) → 1,25-dihydroxyvitamin D₃ (calcitriol — the biologically active form). Calcitriol binds the VDR (vitamin D receptor), a nuclear transcription factor of the steroid hormone receptor family, which then dimerizes with RXR and binds vitamin D response elements (VDREs) in the promoter regions of target genes. The VDR is expressed in virtually every nucleated cell in the body — not just bone and intestine — and the vitamin D-VDR complex regulates approximately 3–5% of the human genome (an estimated 900–2,000 genes), including genes controlling calcium homeostasis, immune cell differentiation, cell proliferation, apoptosis, and angiogenesis.
41% Deficient
NHANES prevalence data — Forrest KY and Stuhldreher WL (2011, Nutrition Research): analysis of NHANES 2005–2006 data (N=4,495 U.S. adults); deficiency defined as 25-OH-D <20 ng/mL (50 nmol/L — the Endocrine Society's minimum sufficiency threshold): 41.6% of U.S. adults deficient; BY RACE: Non-Hispanic Black: 82.1% deficient (elevated melanin reduces UVB photon availability for vitamin D synthesis at the same sun exposure as lighter-skinned individuals; equivalent sun exposure by clock hours is not equivalent for vitamin D synthesis); Hispanic: 69.2%; Non-Hispanic White: 30.9%; BY BODY WEIGHT: obesity (BMI >30): vitamin D sequestration in adipose tissue → lower serum 25-OH-D at equivalent production; estimated: obese individuals need 2–3× the vitamin D dose to achieve equivalent serum levels; BY AGE: adults >70: reduced dermal 7-dehydrocholesterol content + reduced outdoor activity + reduced renal 1α-hydroxylase activity → triple hit to vitamin D production; LATITUDE EFFECTS: Boston (42°N): UVB sufficient for vitamin D synthesis only May–October; Edmonton (52°N): insufficient October–April; Los Angeles (34°N): year-round synthesis possible; UVB seasonality explains winter deficiency peaks even in sun-capable latitudes; CRITICAL SERUM LEVEL DEBATE: the Institute of Medicine (IOM) defines sufficiency as >20 ng/mL (supports bone health); the Endocrine Society clinical practice guideline suggests >30 ng/mL for optimal non-skeletal functions; most functional medicine and longevity-focused practitioners target 40–60 ng/mL based on epidemiological associations; levels above 100 ng/mL may be associated with adverse outcomes (hypercalcemia risk)
VITAL Trial
the largest vitamin D RCT — Manson JE et al. (2019, NEJM): VITAL (VITamin D and OmegA-3 TriaL); DESIGN: 2×2 factorial RCT; N=25,871 U.S. men (≥50 years) and women (≥55 years); interventions: vitamin D₃ 2,000 IU/day vs placebo; omega-3 (fish oil) 1g/day vs placebo; duration: 5.3 years; CARDIOVASCULAR PRIMARY ENDPOINT: no significant reduction in major cardiovascular events (MI, stroke, cardiovascular death) — HR 0.97, p=0.69; CANCER PRIMARY ENDPOINT: no significant reduction in incident cancer overall — HR 0.96, p=0.42; IMPORTANT SECONDARY ANALYSES: cancer mortality (pre-specified secondary): significant −25% reduction (HR 0.75, p=0.02); advanced/metastatic cancer: significant −17% reduction; the cancer mortality signal appeared only after 2 years of follow-up (supporting the hypothesis that vitamin D influences cancer progression and survival rather than initiation of new cancers); non-melanoma skin cancer: no reduction; SUBGROUP ANALYSES: individuals not taking supplemental vitamin D at baseline showed larger cancer benefit (those already supplementing had partial pre-trial correction of deficiency); normal weight individuals showed larger cancer benefit than overweight/obese (consistent with adipose sequestration reducing bioavailability); African Americans: trend toward larger cancer benefit; INTERPRETATION: VITAL does not support vitamin D for primary cardiovascular prevention; it does support a cancer mortality benefit — particularly for established cancer survival; a follow-up meta-analysis incorporating VITAL (Zhang 2019, BMJ): five large RCTs of vitamin D supplementation, N=52,713: cancer mortality −12% overall, −25% with extended follow-up; the cancer mortality benefit is now one of the more robust signals in vitamin D supplementation research
D3 vs D2 vs Calcifediol
forms comparison — three major supplemental forms differ in potency, onset, and use case: VITAMIN D₃ (cholecalciferol): animal-derived (lanolin from sheep wool is the primary commercial source; some vegan D3 from lichen); requires hepatic 25-hydroxylation and renal 1α-hydroxylation to become active calcitriol; onset: slow (2–4 months to reach steady-state serum 25-OH-D with daily dosing); Tripkovic 2012 meta-analysis (American Journal of Clinical Nutrition): D3 is 87% more potent than D2 at raising and maintaining serum 25-OH-D; the half-life of D3 in the body is approximately 2 weeks vs 2 days for D2; VITAMIN D₂ (ergocalciferol): plant/yeast-derived; converted to 25-hydroxyvitamin D₂ in the liver; less potent; shorter half-life; preferred only when vegan sourcing is required; prescription vitamin D in the US (Drisdol, 50,000 IU weekly doses) is D2 — this is a historical artifact, not an evidence-based preference; CALCIFEDIOL (25-hydroxyvitamin D₃ — Rayaldee): the hepatically pre-hydroxylated form; skips the liver conversion step; advantage: faster serum 25-OH-D elevation (onset in days, not months) and more consistent absorption; advantage for: liver disease (impaired hepatic 25-hydroxylation); malabsorption syndromes (calcifediol is more water-soluble than D3 → better absorbed without dietary fat); patients needing rapid 25-OH-D correction; FDA-approved for secondary hyperparathyroidism in CKD; 30μg calcifediol ≈ 1,000 IU D3 in terms of 25-OH-D raising effect; CALCITRIOL (active form): bypasses all conversion; used in renal failure (kidneys can't make calcitriol); NOT appropriate for general supplementation — extremely narrow therapeutic window, easily causes hypercalcemia; requires prescription and close monitoring
Vitamin K2
the calcium routing partner — the clinical rationale for combining vitamin D with vitamin K2: MECHANISM: vitamin D increases intestinal calcium absorption (via TRPV6 channel and calbindin upregulation) AND increases osteocalcin production by osteoblasts; the problem: vitamin D alone does not determine where absorbed calcium goes — whether into bone (desired) or into soft tissue/arteries (undesired); VITAMIN K2 ROLE: K2 (specifically menaquinone-7, MK-7 — the long-chain form from natto and supplements) activates two critical Gla proteins: OSTEOCALCIN (bone Gla protein): carboxylated by K2 → binds calcium into hydroxyapatite in bone matrix; without K2, osteocalcin is undercarboxylated (ucOC) and cannot bind calcium effectively → calcium absorbed but not incorporated into bone; MATRIX GLA PROTEIN (MGP): carboxylated by K2 → inhibits vascular calcification (soft tissue calcium deposition); without K2, MGP is uncarboxylated → cannot prevent arterial calcium deposition → calcification risk increases; OBSERVATIONAL EVIDENCE: Geleijnse JM et al. (2004, Journal of Nutrition): Rotterdam Study, N=4,807; highest vs lowest K2 intake: −41% risk of coronary heart disease mortality and −57% risk of aortic calcification; K2 intake was inversely associated with cardiovascular mortality independent of K1 (K2 is the relevant form, not K1); FORM: MK-7 (menaquinone-7): long half-life (~72 hours); stays in circulation longer; more effective at activating MGP; derived from natto (Japanese fermented soybeans) or bacteria; dose: 100–200μg MK-7 daily; MK-4 (menaquinone-4): shorter half-life; used in osteoporosis prevention in Japan at pharmacological doses (45mg/day — prescription); CAVEAT: K2 (not K1) interacts with warfarin — patients on warfarin should NOT supplement K2 without hematologist guidance; K1 also interacts but K2 more significantly
Want the full evidence writeup?
The Stack Protocol builds four complete goal stacks — Energy, Focus, Sleep, Longevity — with exact doses, timing, budget tiers, and a 30-day rollout plan, graded with the same evidence framework behind this page.
Get the Stack Protocol → $19
Vitamin D Forms Comparison
| Form | Source | Conversion Needed | Onset to Effect | Best For | Notes |
|---|
| Vitamin D₃ (cholecalciferol) | Lanolin/lichen (vegan) | Liver → kidney | 2–4 months (daily dosing) | General supplementation; first choice | 87% more potent than D2; longer half-life |
| Vitamin D₂ (ergocalciferol) | Plants/yeast | Liver → kidney | 2–4 months | Vegan preference only | Less potent; shorter half-life; avoid for optimization |
| Calcifediol (25-OH-D₃) | Synthetic | Kidney only | Days to weeks | Liver disease; malabsorption; rapid repletion | Rx (Rayaldee); more consistent absorption; water-soluble |
| Calcitriol (1,25-OH₂-D₃) | Synthetic | None | Hours | Renal failure (CKD) only | Rx only; extremely narrow TI; causes hypercalcemia at excess doses |
Vitamin D Protocol — Testing, Dosing, and K2 Pairing
Test first — the only way to dose correctly: serum 25-OH-D test is widely available; request at annual physical; insurance-covered for deficiency risk (obesity, limited sun exposure, dark skin, age >65, GI malabsorption); INTERPRETATION: <20 ng/mL: deficient — treat aggressively; 20–29 ng/mL: insufficient — supplement; 30–39 ng/mL: approaching adequacy; 40–60 ng/mL: optimal range (most functional medicine practitioners, Endocrine Society guidelines suggest 30–50 ng/mL; 40–60 ng/mL is the range associated with lowest all-cause mortality in observational studies); >100 ng/mL: potential toxicity range — hypercalcemia risk; retest at 3 months after starting supplementation to confirm adequate response and avoid overdosing.
Dosing by baseline 25-OH-D level: DEFICIENT (<20 ng/mL): 5,000 IU D3 daily × 8–12 weeks, then retest and drop to maintenance; INSUFFICIENT (20–29 ng/mL): 2,000–4,000 IU D3 daily; MAINTENANCE (achieving 40–60 ng/mL): 1,500–2,000 IU D3 daily; most adults in northern latitudes who do not supplement fall to 15–25 ng/mL by winter; a daily year-round dose of 2,000 IU D3 maintains most adults in the 30–50 ng/mL range; SPECIAL POPULATIONS: obesity: 2–3× standard dose needed; elderly (>65): 2,000–4,000 IU recommended; dark skin at northern latitudes: 3,000–5,000 IU through winter months; TAKE WITH FAT: D3 is fat-soluble — take with the largest fat-containing meal of the day (lunch or dinner) for optimal absorption; studies show 50–57% better absorption when taken with a fat-containing meal vs fasted; VITAMIN K2 PAIRING: 100–200μg MK-7 daily with vitamin D3; most easily done with a combined D3+K2 supplement; essential for anyone taking >2,000 IU D3 daily; MAGNESIUM CO-FACTOR: magnesium is required for vitamin D hydroxylation steps (CYP2R1 and CYP27B1 are magnesium-dependent enzymes); magnesium deficiency impairs vitamin D activation; supplementing D3 without addressing magnesium deficiency may produce lower-than-expected 25-OH-D increases — address magnesium (see StackProtocol's Magnesium guide) concurrently with vitamin D.
Vitamin D3 + K2 MK-7 →
Vitamin D Test Kit →
More evidence-based supplements
As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.